Biosimulation Companies-Corporate Milestones, Recent Strategic Partnerships, Competitive Positioning, Transaction Synergies and Financial Performance Evaluation

Top Companies in the Biosimulation Market

The global biosimulation market size is calculated at USD 3.97 billion in 2024, grew to USD 4.64 billion in 2025, and is projected to reach around USD 18.97 billion by 2034. The market is expanding at a CAGR of 16.94% between 2024 and 2034.

Top companies in the biosimulation market are ANSYS, Inc., Atomwise, Inc., BioSymetrics, Inc., Cadence, Cellworks Group, Inc., Certara, Inc., Exonate, Exploristics, Genedata AG, Schrodinger, Simulations Plus and VeriSim Life.

Latest Announcements by Industry Leaders

Max Kanevsky, Chief Technology Officer, Certara, commented on the launch of its Phoenix 8.5 software launch that the company develops software solutions that transform research data into trustworthy insights for scientists and regulators to bring new medicines to market faster. The latest version of their software includes new capabilities requested by existing clients and their IT business partners.

Recent Developments in the Biosimulation Market

• In September 2024, Cellworks Group, Inc. announced positive results from a study involving Cellworks’ biosimulation platform to accurately predict overall survival (OS) and chemotherapy benefits in two non-small cell lung cancer patients’ cohorts, thereby advancing personalized treatment.
• In January 2023, Callworks announced the launch of two separate business units employing biosimulation and computational biosimulation model (CBM) to test potential new precision oncology drugs in both pre-clinical and clinical stages.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com | +1 804 441 9344